SCHEMBL6986386

SCHEMBL6986386

CC1=CC(=O)CC(c2cccnc2)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 8/20 0.46
CHRNA4 P43681 8/20 0.46
CHRNA7 P36544 7/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CYP2A6 P11509 3/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
KDM4E B2RXH2 2/20 0.41
CYP3A4 P08684 1/20 0.41
THRB P10828 1/20 0.41
TSHR P16473 1/20 0.41
THPO P40225 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6979945 0.82 BRD4 (0.45) MEN1KMT2APOLBSMN1; SMN2MAPK1
SCHEMBL6985292 0.79 CHRNB2 (0.41) CHRNB2CHRNA4CHRNA7MEN1KMT2A
SCHEMBL156842 0.79 CHRNB2 (0.56) CHRNB2CHRNA4CHRNA7MEN1KMT2A
SCHEMBL6981391 0.75 MAPT (0.43) MEN1KMT2ATSHRNPSR1ALDH1A1
SCHEMBL11621077 0.74 CYP11B2 (0.47) CHRNB2CHRNA4CHRNA7MEN1KMT2A
SCHEMBL6982349 0.73 POLB (0.46) MEN1KMT2ACYP2D6CYP2C19POLB
SCHEMBL1100609 0.72 CHRNB2 (0.49) CHRNB2CHRNA4CHRNA7MEN1KMT2A
SCHEMBL6985384 0.70 BACE1 (0.40) CYP2D6CYP2C19POLBCYP1A2CYP2C9
SCHEMBL10242198 0.69 CHRNB2 (0.53) CHRNB2CHRNA4CHRNA7MEN1KMT2A
SCHEMBL15744014 0.69 KDM4E (0.50) CHRNB2CHRNA4CHRNA7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1145612-C New 1- aza-2-alkyl-6-aryl-cyclanes compound, its producing process and medical composition containing them 2004-04-14 CN disclosed
EP-1050530-B1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers SERVIER LAB (FR) 2003-10-22 EP disclosed
US-6451789-B1 CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS LES LABORTOIRES SERVIER (FR) 2002-09-17 US disclosed
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes RAULT SYLVAIN (FR) 2002-04-11 US disclosed
US-6323222-B1 COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS ADIR ET COMPAGNIE (FR) 2001-11-27 US disclosed
EP-1050530-A1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers ADIR ET COMPAGNIE (FR) 2000-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes SULT2A1, GRIN2A, NR3C1 CHRNB2 344/4885CHRNA4 85/4885CHRNA7 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.